


Chemoenzymatic synthesis of protein pseudo-[2]rotaxane

Elodie Soehnlen,¹ Shalene Ofner,¹ Judit Osz,² Natacha Rochel,² Vladimir Torbeev,¹

¹Équipe de Chimie des Biosystèmes, ESBS, UMR 7242 Biotechnologie et Signalisation Cellulaire, Illkirch, France

²Équipe de Chimie biophysique de la signalisation transcriptionnelle, Institut de Genetique et de Biologie, Moléculaire et Cellulaire (IGBMC), INSERM (U1258), University of Strasbourg, CNRS, UMR 7104, Illkirch, France



Introduction : Intrinsically disordered proteins (IDPs) display enhanced conformational flexibility and structural heterogeneity. They are able to recognize diverse molecular targets and engage in multivalent interactions¹. For instance, transcriptional co-activators ACTR (p160) and p300/CBP contain IDP regions which are involved in the formation of multiprotein complexes with nuclear receptors regulating the transcription of many genes. These proteins are overexpressed in breast and ovarian cancers^{2,3}.

Goal of the project :

Target and disrupt protein-protein interactions between ACTR and NCBD. To do this, we want to increase the stability of the ACTR/NCBD complex by linking the two domains through non-covalent interactions enhanced by non-classical topology (pseudo-[2]rotaxane protein complex).

Complex :

Chemoenzymatic synthesis

Native Chemical Ligation (NCL)

1. NaNO₂, pH3, -15°C
2. MPAA, pH6.5, R.T.

ACTR1-B-NHNH₂ → ACTR1-B-SR

Peptide hydrazide → Peptide thioester

2. NCL reaction: Amide bond formation

ACTR1-B-SR + ACTR2-B-NH₂ → ACTR1-B-S-CO-ACTR2-B

TCEP, phosphate buffer pH6.5

S to N acyl shift

Enzyme asparaginyl endopeptidase

OaAEP1b from *Clavibacter alfalfae* (Kalata B1)

Motif of recognition for cyclization by OaAEP1b

STNRNGLP-COOH

AEP activation and improvement of the catalytic efficiency with AEP C247A mutant

90% purity Yield = 4.2%

98% purity Yield = 48%

1. Hydrazide to azide
2. Azide to thioester

Cyclization

0 min, 4 min, 6 min, 8 min, 10 min, 14 min

* = OaAEP1-b C247A
* = ACTR-B
* = cACTR-B

Production and purification of AEP C247A mutant

E. Coli transformation by heat shock (E. coli SHuffle T7 Express cells)

Picking colony and starting small culture

At OD ~ 0.8, IPTG induction overnight at 18°C

1. Ni affinity chromatography
2. Buffer exchange (low salts dialysis)
3. Activation pH4: Dialysis in activation buffer

Yield = 1.8 mg/L AEP C247A

LC-MS and analytical HPLC analysis of purified cACTR-B (MW = 5978.55 g/mol)

1. Native Chemical Ligation (NCL)
2. Desulfurization
3. HPLC purification

95% purity Yield = 31.4%

1. OaAEP1b enzyme (0.2 μM) in activation buffer (100 mM NaOAc, 50 mM NaCl, 1 mM EDTA, pH = 6.2)
2. HPLC purification

96% purity Yield = 80%

Monitoring of enzyme activation by FRET

FRET Quenching

FAM = fluorescein (fluorophore) and a 3,5-Dinitrotyrosine (quencher)

Excitation at 495 nm and measure of fluorescence intensity at 510 nm

Activity buffer:
- 100 mM NaOAc, pH4
- 500 mM NaCl
- 5% glycerol

Concentrations (μM)	SP2	SP3	Aep Act.	Aep (16/07/21)	NM013 (substrat)	Ac-YVAD-CMK (inhibitor)	Ctrl + : MN004 (desired product ref.)
	1.02	0.6	24.9	0.6	0.5	15	0.5

Biophysical characterization and cell penetration studies

Circular Dichroism (CD)

Helicity (%)

Variant	Helicity (%)
ACTR-B	9.5
cACTR-B	9.9
NCBD	47.0
ACTR-B/NCBD	42.0
cACTR-B/NCBD	38.5
cACTR-B/NCBD-2	40.3

Thermal Denaturation (TD)

Variant	Thermal denaturation
ACTR-B/NCBD	86°C
cACTR-B/NCBD	79°C
ACTR/NCBD W.T.*	67°C
ACTRαMex3*	110°C

* Data from Alexis Jouin, PhD student in the team of Biosystem chemistry

Isothermal Titration Calorimetry (ITC) of cACTR-B

Series of 23 injections of cACTR-B solution into NCBD solution

Variant	K _d (nM)	ΔH (cal.mol ⁻¹)	ΔG (kcal.mol ⁻¹)	-TΔS (kcal.mol ⁻¹)
cACTR-B	170.0	-16344	-9.4	6.9
ACTRwt	206.0	-12700	-9.3	3.4

→ Better binding for cACTR-B than W.T.
→ Decreasing of enthalpy and increasing of entropy → More interaction that stabilize the complex and destabilization because less freedom of conformation degree (enthalpy-entropy compensation)

Fluorescence polarization measurement (FP measurement)

Direct FP measurement: Binding study of cACTR-B/NCBD complex (N=3)

Variant	K _d (nM)
ACTR-B	167.7
cACTR-B	102.1
ACTRwt	57.7

⚠ FITC is not in the same place for ACTRwt than ACTR-B and cACTR-B

Competition binding experiment: Targeting NCBD domain in full length 265 kDa CBP (N=3)

Concentration	Nano polarization (np)
Control	5.47
FITC-ACTRwt	6.57
FITC-ACTRwt/competition with cACTR-B	6.37
FITC-ACTRwt/competition with ACTR-B	9.07
FITC-ACTRwt/competition with ACTR-B-AEP	10.03
FITC-ACTRwt/competition with ACTR-B-AEP (1 μM)	25.67
FITC-ACTRwt/competition with ACTR-B-AEP (10 μM)	20.10
FITC-ACTRwt/competition with ACTR-B-AEP (10 μM)	13.43
FITC-ACTRwt/competition with ACTR-B-AEP (1 μM)	15.97
FITC-ACTRwt/competition with ACTR-B-AEP (1 μM)	24.20

Binding of cACTR-B to full length CBP is confirmed → Binding mechanism ?

Cell penetration studied by confocal microscopy

ACTR-B vs cACTR-B

Cell uptake of ACTR-B and cACTR-B (10 μM peptide, 1h treatment in PBS, U2OS cell line)

Quantitative determination of cell uptake by flow cytometry

U2OS Cells 1hr

Mean fluorescence intensity of CF-cACTR-B (10 μM) and CF-ACTR-B (10 μM) (p-value = 0.014) (1 h treatment at 37°C in PBS)

Conclusion and perspectives

ACTR-B could be chemically synthesized and cyclized enzymatically via the ligase asparaginyl endopeptidase. cACTR-B/NCBD pseudo-[2]rotaxane complex was formed. CD analysis shown a helical structure similar for ACTR-B/NCBD and cACTR-B/NCBD complex. We proved that complex cACTR-B/NCBD and ACTR-B/NCBD have a higher thermal denaturation than ACTRwt/NCBD. It was found that cACTR-B is a better binding with NCBD compare to ACTRwt. Fluorescence polarization measurement allowed us to see a binding between cACTR-B and NCBD, but also full length CBP. For the future it would be interesting to determine the binding mechanism between this cyclic cACTR-B and NCBD (and CBP) and get a cristal structure of the complex. The next step will be to study the biological impact of cACTR-B into cells.

References

- Oldfield C. J. and Dunker A. K., *Annu. Rev. Biochem.*, 2014, 83, 553–584
- Demarest S.J., Martinez-Yamout M., Chung J., Chen H., Xu W., Dyson H. J., Evans R. M., and Wright P. E., *Nature*, 415, 549–553, 2002
- Shammas S. L., *Curr. Opin. Struct. Biol.*, 2017, 42, 155–161
- Harris K. S., Durek T., Kaas Q., Poth A. G., Gilding E. K., Conlan B. F., Saska I., Daly N. L., van der Weerden N. L., Craik D. J., Anderson M. A., *Nat. Commun.*, 2015